Exelixis Inc. Stock
Exelixis Inc. Stock
Heavy losses for Exelixis Inc. today as the stock fell by -€2.600 (-5.350%).
With 19 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
On the other hand, the target price of 44 € is below the current price of 46.01 € for Exelixis Inc., so the potential is actually -4.36%.
So far the community has only identified positive things for Exelixis Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Exelixis Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Exelixis Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Exelixis Inc. | -5.350% | -0.726% | 1.953% | 50.527% | 26.064% | 169.703% | 241.851% |
| Ligand Pharmaceuticals | -1.540% | -3.759% | -7.246% | 118.803% | 54.217% | 316.260% | 167.056% |
| United Therapeutics | -1.560% | -2.019% | -3.756% | 84.880% | 6.740% | 104.989% | 194.258% |
| Ionis Pharmaceuticals Inc. | -2.030% | -5.964% | -34.579% | 21.707% | -32.019% | 27.978% | 47.510% |
Comments
Exelixis (EXEL) had its "buy" rating reaffirmed by HC Wainwright. They now have a $56.00 price target on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis (EXEL) had its "buy" rating reaffirmed by UBS Group AG.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis (EXEL) had its price target raised by HC Wainwright from $54.00 to $56.00. They now have a "buy" rating on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
News
These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead
If you had invested in Krystal Biotech (NASDAQ: KRYS), Exelixis (NASDAQ: EXEL), or CVS Health (NYSE: CVS) at the beginning of the year, you'd be sitting pretty. All three companies have outpaced the
Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near
Key Points
- Interested in Exelixis, Inc.? Here are five stocks we like better.
- Exelixis is leaning on CABO growth in renal cell carcinoma and neuroendocrine tumors, with management emphasizing
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist
A few healthcare companies garner much of the attention in the sector. The list includes Eli Lilly, Johnson & Johnson, UnitedHealth Group, and several others. However, beyond those giants, there are